PD-1/PD-L1 inhibitors can normalize tumor vasculature by promoting γ-interferon production and activating effector T cells, thereby enhancing the killing function of effector T cells and the efficacy of VEGF inhibitors. The gene discussed is CD274; the disease is neoplasm.